ArticleInternational journal of retina and vitreous2026
Add-on implantation of the smaller-incision new generation implantable miniature telescope (SING IMT™) in pseudophakic eyes.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo describe a novel surgical technique for add-on sulcus implantation of the Smaller-Incision New Generation Implantable Miniature Telescope (SING IMT™) in pseudophakic eyes with end-stage age-related macular degeneration (AMD).
methodsTwo pseudophakic patients with bilateral end-stage AMD underwent add-on SING IMT™ implantation in the ciliary sulcus. Pre- and postoperative evaluations included best-corrected distance visual acuity (BCDVA), anterior segment OCT (AS-OCT), corneal endothelial cell counts, and subjective visual function assessments, with follow-up to 6 months.
resultsBoth surgeries were uneventful. The devices remained stable and well-centered with no significant inflammation, corneal decompensation, or intraocular pressure elevation. BCDVA improved by 3–4 ETDRS lines, and both patients reported improved daily visual function. Corneal endothelial loss was < 5% at 6 months.
conclusionsAdd-on sulcus implantation of the SING IMT™ in pseudophakic eyes is surgically feasible and well tolerated, expanding the potential indications of this visual rehabilitation device to a broader AMD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.